KUALA LUMPUR: Malaysian Genomics Resource Centre Bhd (MGRC) returned to the black in the second quarter ended Dec 31, 2019, with a net profit of RM24.2 mil, against a net loss of RM991,000 in the same period in 2018.
In a filing with Bursa Malaysia today (Feb 18), MGRC said its revenue rose to RM4.96 mil from RM103,000 mainly due to dividend from MPath Group.
On Dec 24, 2019, MGRC completed the disposal of its entire clinical pathology services business, held under MPath to Gribbles Pathology (Malaysia) Sdn Bhd, which is indirectly owned by Singapore-based Pathology Asia Holdings Pte Ltd.
Moving forward, MGRC will focus on growing its genetic screening services business with new products. – Feb 19, 2020, 2020, Bernama.
